Menlo Ventures' inaugural 2025: The State of AI in Healthcare Report

Nelson Advisors
3 hours ago
14 min read

The AI Inflection Point: Strategic Review of Menlo Ventures' 2025 State of AI in Healthcare

Executive Summary: The End of the Laggard Era

Strategic Overview: The Flipped Script

The inaugural 2025: The State of AI in Healthcare Report from Menlo Ventures marks a critical inflection point, confirming that the healthcare industry has decisively moved past its entrenched reputation as a digital laggard. The analysis demonstrates a profound reversal, positioning the $4.9 Trillion industry as a leader in enterprise AI adoption. This accelerated commitment is quantified by key adoption metrics: the sector is now deploying AI at 2.2 times the rate of the broader economy.

This transformation is not theoretical; it is validated by a massive infusion of capital directed at operational deployment. Total AI spending in healthcare surged to $1.4 Billion in 2025, representing nearly a three-fold increase from the previous year’s total. Crucially, the vast majority of this capital is allocated to production deployments, signalling the decisive end of the proof-of-concept and piloting phase for market leaders.

Organisations are prioritising trusted, production-ready solutions, willing to pay a premium for systems that mitigate the significant risks associated with failure, including operational disruption, patient harm, and reputational damage.

The investment strategy is overwhelmingly focused on financial and operational triage. Providers dominate the expenditure, accounting for $1 Billion, or 75% of the total spend.This capital is concentrated in areas promising immediate, measurable ROI, primarily ambient clinical documentation (representing $600 Million) and back-office Revenue Cycle Management (RCM) automation ($450 million). These investments directly target the industry’s most pressing operational crises: pervasive physician burnout, critical labor shortages, and administrative overhead that severely compresses margins.

Identified Market Dynamics and Strategic Imperatives

The rapid acceleration observed in the provider segment is not uniform across the entire healthcare ecosystem. The marketplace is undergoing significant strategic bifurcation. While health providers (systems and outpatient facilities) have aggressively shortened their procurement timelines (by 18% to 22%), payers have seen their buying cycles lengthen by 20%.This divergence reflects fundamentally different postures toward AI, with providers treating adoption as a necessity driven by immediate operational distress, while payers remain more cautious and deliberative, focused on risk mitigation and internal experimentation.

The dramatic increase in adoption velocity, evidenced by the 7x increase in deployed solutions over 2024, suggests a fundamental shift in the strategic mandate for large health systems. AI is no longer categorized as an optional efficiency tool but has become a mandatory, defensive operational strategy. The acute post-pandemic environment, characterized by rising labor costs and administrative complexity, has amplified the cost of inaction beyond the cost of adoption. This structural urgency explains why a leading institution like Kaiser Permanente executed the largest generative AI rollout in healthcare history, Abridge's ambient documentation solution, faster than any technology implementation in the organisation’s preceding 20 years.

The AI Imperative: Scale, Velocity, and Institutional Commitment

Quantifying the Acceleration and Domain Specialisation

The velocity metrics underscore the depth of this transformation. Healthcare’s adoption rate is 2.2 times faster than the broader economy, driven by the deployment of specialised, domain-specific AI tools.Across the industry, 22% of healthcare organisations have now deployed these domain-specific solutions, representing a massive seven-fold increase over the figures reported in 2024. This data validates the necessity for purpose-built, industry-specific AI models tailored to the clinical, regulatory, and technical complexity of healthcare workflows, contrasting sharply with the broader economy’s slower adoption of more generalised LLM applications.

Adoption leadership is concentrated heavily among providers. Health systems are pioneering the transformation, demonstrating 27% adoption of specialised AI, significantly outpacing outpatient providers (18%) and payers (14%). This concentration of activity has fueled a thriving ecosystem of high-value start-ups, resulting in the creation of eight AI unicorns across key areas like medical documentation, Revenue Cycle Management (RCM), and payer operations—more than any other vertical AI category examined.

Case Studies in Institutional Execution

Leading health systems are making commitments that signal the institutionalisation of AI as a core strategic pillar:

Kaiser Permanente: The successful, large-scale deployment of Abridge’s ambient documentation solution across 40 hospitals and over 600 medical offices serves as a crucial benchmark. This rollout, noted for being the largest generative AI implementation in healthcare history, demonstrates that large-scale, complex health systems can achieve unprecedented deployment speed when the strategic value proposition is sufficiently compelling and the technology is mature.
Advocate Health: This organisation has adopted a systematic, portfolio approach to AI integration, evaluating more than 225 potential AI solutions before selecting 40 specific use cases for production deployment. These use cases span key areas including the largest deployment of Microsoft Dragon Copilot, advanced imaging tools like Aidoc and Rad AI, and AI integration into call centre operations. The organisation projects these initiatives will result in a documentation time reduction of more than 50%.
Mayo Clinic: The institution’s commitment to AI is demonstrated by an investment exceeding $1 Billion across more than 200 projects over the coming years. This major investment signals a strategy that extends far beyond immediate administrative automation, explicitly targeting complex applications in diagnostics, patient care, and clinical decision support.

The rapid deployment of administrative "quick win" tools is a deliberate strategy used by leading systems to build the necessary technical and compliance infrastructure, the "operational muscle", required for sustained AI integration. By securing early, measurable wins in lower-risk domains, these organisations are de-risking the complex internal political, technical, and change management landscape, establishing proven frameworks for AI governance and rapid deployment that will ultimately accelerate future investments into high-stakes clinical areas, as exemplified by Mayo’s substantial commitment.

Capital Allocation Analysis: Deconstructing the $1.4 Billion Surge

Provider Dominance and Expenditure Focus

The distribution of the $1.4 Billion in AI spending clearly illustrates the acute pain points driving current market behaviour. Providers are the dominant purchasers, supplying $1 Billion (75%) of the total capital flow, driven by the urgent need to stabilise thin margins, mitigate administrative burdens, and combat significant post-pandemic staff shortages.

The expenditure is heavily concentrated in the "Big Two" categories that offer the most immediate and tangible operational relief:

Ambient Clinical Documentation: Accounting for $600 Million in spending, this is the largest single AI category. The primary value proposition is the reduction of physician burnout by automating the historically time-consuming process of note-taking and EHR population.
Coding and Billing Automation (Back-Office RCM): This category commands $450 Million in spending. Its focus is on recovering lost revenue by automating complex coding workflows and mitigating claim errors and denials, offering a direct financial return on investment.

The allocation of over $1 Billion to these two areas, documentation and RCM, confirms that immediate financial stability and staff retention are the paramount investment drivers in 2025. Purely clinical AI applications, while vital for the future, are often being funded by the efficiency savings generated through the successful deployment of these operational AI systems. This spending pattern is a direct reflection of economic distress compelling technological adoption, rather than solely a reaction to clinical breakthroughs.

Emerging Hyper-Growth Categories: Unlocking New Budgets

Beyond the dominant categories, AI is creating new markets by solving service gaps that were previously unaddressable by traditional software. These segments exhibit hyper-growth due to their potential to convert expensive, manual services dollars into scalable software revenue:

Prior Authorisation: This process, widely regarded as healthcare's "most reviled administrative process," is also one of the largest opportunities for streamlining. AI has already created a $100 Million-plus market in this space, experiencing a rapid growth rate of +10x year-over-year. AI solutions augment or replace staff who traditionally spent hours on calls or filling out forms, compressing authorisation times from days to minutes.
Patient Engagement/Call Centres: Focused on leveraging voice-enabled AI to augment staff and improve patient access, this segment represents a $100 Million-plus market. It exhibits the highest velocity growth, accelerating at +20x year-over-year.

The rapid growth in Prior Authorisation and Patient Engagement (10x and 20x YoY, respectively) demonstrates that venture capital valuations are rewarding companies that successfully automate manual workflows. These solutions are generating new revenue streams by automating services that were never traditionally considered part of the IT budget, efficiently addressing the massive $740 Billion annual U.S. healthcare administration cost base.

Procurement and Adoption Dynamics: The Bifurcated Marketplace

Provider Speed: Urgency and Decisive Action

The provider segment, comprising health systems and outpatient facilities, is demonstrating an unprecedented urgency in AI procurement. Health systems have reduced their average buying cycles by 18% (from 8.0 months to 6.6 months), while outpatient providers have seen an even greater improvement, shortening cycles by 22% (from 6.0 months to 4.7 months). This compression reflects a clear strategic alignment to rapidly capture operational gains and alleviate organisational pressure.

Provider decision-making is governed by three primary criteria for selecting AI partners and solutions

Maturity of technology: Prioritising production-ready solutions that demonstrate reliable performance at scale.
Level of risk to patient care: Tools that do not directly interface with or expose patients to risk achieve faster approval and deployment timelines.
Short-term value delivery: Focusing on quick wins and rapid ROI generation to maintain momentum and internal credibility.

The willingness of organisations to pay a premium for trusted AI solutions, rather than prioritizing cost minimisation, underscores a strategic focus on de-risking operations and ensuring long-term reliability.

Payer Deliberation: Caution and Risk Transfer

In stark contrast to the acceleration observed among providers, the payer sector is exhibiting strategic caution. Payer procurement cycles have lengthened by 20%, increasing from 9.4 months to 11.3 months.

Payers remain largely "AI-curious," confined primarily to piloting and internal experimentation. Their reluctance to move quickly into large-scale production deployments stems from a strategic concern: that increasing provider efficiency (e.g., faster RCM and billing submissions) will lead to a surge in claims volume and overall increased medical costs. Currently, payer AI spending is negligible ($50 Million) and focused predominantly on internal, generalised LLM applications, such as summarising clinical literature, rather than core workflow automation.

This lengthening of payer cycles is interpreted as a short-term, defensive mechanism against the escalating efficiency of provider workflows. However, as provider adoption continues to accelerate, particularly in high-stakes, volume-driving areas like prior authorisation (growing 10x YoY), the operational and political pressure on payers to match this velocity will increase dramatically. This divergence creates a unique arbitrage opportunity for startups: by focusing on optimising workflows exclusively for the provider (where the capital and urgency reside), they effectively force the hand of the payer to eventually invest in counter-automation solutions to manage the claims influx.

The pharmaceutical and biotech segments are following a different path, maintaining steady 10-month buying cycles. These companies are focused primarily on building proprietary models rather than adopting off-the-shelf vendor IT solutions.

Comparative AI Procurement Cycles

Stakeholder Segment	Traditional IT Cycle (Months)	AI Solution Cycle (Months)	Change	Adoption Stance
Health Systems (Providers)	8.0	6.6	18% Acceleration	Rapid Deployment of Production Systems
Outpatient Providers	6.0	4.7	22% Acceleration	Urgency to Capture Operational Gains
Payers	9.4	11.3	20% Lengthening	Deliberate, AI-Curious, Risk Mitigation
Pharma/Biotech	$\approx $10	$\approx$10	Steady	Focused on Piloting/Proprietary Model Building

The Competitive Landscape: Startups, Incumbents and Disruption Risk

Generative AI Dominance by Challengers

The introduction of generative AI has created a clear market dislocation: 85% of all generative AI spending in healthcare currently flows to AI-native startups, rather than established incumbents.

This market disparity is attributed to a structural advantage held by challengers. Startups are unburdened by legacy technical debt and the bureaucratic inertia of larger organisations, allowing them to design products natively around sophisticated AI capabilities. This is vividly illustrated in the ambient scribing market, where AI-native companies like Abridge (30% market share) and Ambience (13% market share) have captured nearly 70% of the new generative AI market, effectively challenging the large incumbent Nuance’s DAX Copilot (33% market share).

The Imminent Commoditisation of Point Solutions

Despite the strong initial revenue capture by AI-native challengers, the market is already exhibiting signs of instability and commoditisation. The success of ambient scribes is tempered by a critical weakness: weak stickiness. Up to 67% of outpatient providers expect to switch their scribing vendor within three years, viewing the core technology as increasingly commoditised. Similarly, large health systems report being equally likely to switch as they are to remain with their current vendor.

This significant churn pressure necessitates that successful startups immediately leverage their initial revenue lead to expand rapidly beyond mere documentation. Survival requires transitioning from a single-feature point solution to a comprehensive, integrated AI platform capable of solving multiple, adjacent workflow problems.This dynamic suggests that the current Generative AI market is functioning as a high-stakes screening process, where failure to expand functionality will likely result in acquisition by incumbents or extinction via commoditisation.

The Incumbent Counter-Attack and the Trust Moat

The major healthcare IT incumbents, including Epic, Oracle Health, and athenahealth, face real disruption risk from the rapid rise of AI-native challengers. Their initial AI offerings have largely been perceived as bolt-on features integrated into legacy platforms.

However, incumbents retain powerful, enduring competitive advantages in distribution, deep integration, and, critically, customer trust. Despite the high revenue capture by startups, customers report a slight preference for purchasing critical, high-risk functions, such as coding, billing automation and clinical decision support (CDS), from their trusted EHR provider. The incumbent counter-strategy relies on leveraging this established trust for core clinical functions and integrating or acquiring successful point solutions as market commoditisation accelerates. The barrier to entry for a high-functioning, integrated, and regulatory-compliant RCM or CDS tool is extremely high, reinforcing the incumbent advantage in mission-critical systems.

Strategic Funding Pathways: Converting Services Dollars to Software

The Total Addressable Administrative Market

The true scale of the opportunity for AI in healthcare is defined by administrative spend. Total U.S. healthcare administration spending reaches an estimated $740 Billion annually. This immense market, historically dominated by manual labour, dwarfs the traditional healthcare IT budget, which is estimated at $63 Billion.Targeting this services budget is the engine for future high-growth valuations.

Dual-Path Budget Acquisition Strategy

AI solutions are gaining budget through two fundamentally different, yet intertwined, paths:

Augmenting Existing IT Spend (Capital Competition): This path involves selling intelligent modules that augment existing IT systems. Solutions in medical documentation and back-office RCM, which comprise approximately $38 Billion of existing IT spend, compete directly within the confines of established IT budgets. This strategy is about improving the efficiency of existing software and workflows, competing for a fixed pool of funds.
Automating Manual Workflows (Capital Creation): This crucial path involves automating complex, labor-intensive workflows that were historically never part of the IT budget. By automating roles in areas like prior authorisation, these AI companies are effectively converting $740 Billion of annual services dollars, previously allocated to staff, into scalable software dollars.

The automation of manual workflows (Path 2) is the engine of high-growth valuations because it represents capital creation. This approach generates new, substantial revenue streams by changing the underlying cost structure of healthcare delivery, offering a significantly stronger value proposition than simply competing for constrained IT budgets (Path 1). The success of companies automating complex processes like prior authorisation demonstrates that AI is fundamentally redefining the necessary staff component, reinforcing the urgency behind the 2.2x adoption rate observed among providers.

The Frontier of Discovery: AI in Life Sciences and Biotech

Proprietary Models and IP Strategy

The adoption curve for life sciences and biotech companies is deliberately slower than that of providers, characterised mostly by piloting and experimentation. This sector's strategy is fundamentally focused on building proprietary defences rather than integrating off-the-shelf software. A significant 66% of pharmaceutical and biotech companies are prioritising the effort to build or fine-tune their own proprietary models, including developing foundation models of biology and drug discovery.

This preference for internal intellectual property suggests that the key competitive advantage in pharma AI is tied directly to the access and proprietary structuring of unique, internal biological and trial data. These organisations perceive massive value in protecting and monetising their decades of internal data.The highest area of interest is R&D data analysis (63%), leveraging AI to accelerate the costly and time-consuming drug discovery lifecycle.

Application Across the Development Lifecycle

While R&D remains the core focus, life sciences organisations are strategically expanding AI use cases beyond laboratory functions and into operational areas across the product lifecycle

Quality and Regulatory: This function shows the highest current adoption rate at 48%, reflecting the utility of AI in managing and ensuring compliance in rigid processes.
Development Stages: Pre-clinical studies show 42% adoption, and clinical trials demonstrate 40% adoption, indicating the immediate value of AI in optimising experimental design and resource allocation.
Operational Functions: Investment priorities also include medical affairs (40% adoption), manufacturing, and commercial operations.

Life Sciences AI Adoption and Model Strategy

Strategic Focus Area	Adoption/Interest Rate (%)	Strategic Implication
Proprietary Model Building/Fine-tuning	66%	Focus on IP creation; AI is a tool to monetize proprietary biological data.
R&D Data Analysis	63%	Primary focus for utilizing AI to accelerate the discovery phase.
Quality and Regulatory	48%	High priority for ensuring compliance and streamlining internal processes.
Pre-clinical Studies	42%	Leveraging AI to reduce the cost and time of early-stage experimentation.

Conclusion and Forward-Looking Recommendations

The Remaining Market Potential and Next Waves

The healthcare AI moment has arrived, characterised by high-velocity adoption and substantial production investment. Despite the tripling of AI spending and unprecedented adoption rates, the report estimates that 80% of the total market remains untapped. This massive, latent opportunity provides a substantial runway for continued innovation and investment over the next decade.

The next waves of strategic growth will be defined by companies that successfully automate the remaining segments of the services economy and deepen their functional integration:

Voice-Enabled AI: Expanding the use of AI beyond mere clinical documentation into complex patient engagement, virtual assistants, and interaction interfaces.
Prior Authorisation at Scale: Fully realising the potential of the +10x YoY growth category by fundamentally solving the systemic friction of this administrative burden, thereby converting a greater share of the $740 Billion administrative services budget.
Disintermediation Platforms: Companies that transcend single point solutions to establish themselves as the essential AI orchestration layer, operating between the clinician workflow and the core EHR system.

Strategic Considerations on Risk and Trust

A non-negotiable factor governing scale remains trust. Healthcare organisations explicitly confirm their prioritisation of trusted AI solutions, viewing the cost of a premium solution as less severe than the potential costs associated with operational failure, reputational damage, or patient harm. This emphasis on trustworthiness dictates that solutions impacting patient safety will continue to face deeper scrutiny and longer timelines than administrative tools.

The high-velocity adoption currently observed in administrative, low-risk domains serves as a crucial, market-driven mechanism for setting deployment standards and building confidence. This established framework for rapid, low-stakes implementation is the necessary blueprint for how high-stakes Clinical Decision Support (CDS) tools will eventually scale, once regulatory and reliability standards reach the threshold of institutional acceptance.

Systemic Transformation: The Future of Healthcare Intelligence

The long-term winners in the healthcare AI ecosystem will not be defined by mere task automation, such as simple scribing, but by their ability to build a comprehensive system of intelligence that enables reasoning, creation, and prediction for the enterprise. This involves moving past Layer 2 (Data preparation) in the modern AI stack and becoming proficient in Layer 3 (Deployment and Orchestration).Successful startups must transition to become the preferred orchestration layer—the operational hub for AI, to sustain market share and truly disintermediate incumbents, rather than remaining commoditised feature providers.

Ultimately, the accelerated adoption rate of AI in healthcare signals a permanent, structural transformation in the industry’s labor market and operational model. By efficiently converting the $740 Billion of services dollars into scalable software revenue, AI is not only lowering administrative costs but is fundamentally redefining staff roles, offering the potential to free up clinicians for higher-value, direct patient care. This re-allocation of resources and capital is the most profound long-term implication of the AI inflection point demonstrated in the 2025 report.

Source: https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/

Nelson Advisors > MedTech and HealthTech M&A

Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech